Theme IntelligenceUpdated May 6, 2026

Biotech & Healthcare Stocks: The Life Sciences Theme Screener and Research Hub

Track large-cap pharma, next-gen gene editing, medical devices, life sciences tools, managed care, and AI-driven drug discovery in one place. Compare revenue growth, R&D efficiency, and pipeline value across the full healthcare stack.

Investment Thesis

A research-first view of life sciences equities — from defensive dividend-paying pharma giants to high-risk, high-reward gene therapy and AI-driven biotech.

GrowthInnovation

Explore the Screener Review Today's Drivers Open Full Screener

Research by Anish DasFounder and Editor

Jump ToPerformance Screener Valuation Intelligence Earnings

Performance Dashboard

How the Biotech & Healthcare theme has traded against the market

Use the basket chart to see whether the move is broad-based or being carried by a narrow set of names.

Biotech & Healthcare Basket +28.1%SPY +29.5%QQQ +41.6%

Equal-weight Biotech & Healthcare basketS&P 500QQQ

Top 1M Performers

Momentum

RVMD$147.21

Revolution Medicines, Inc.

+54.2%

YTD +86%$29B

AXSM$223.06

Axsome Therapeutics, Inc.

+31.4%

YTD +25%$11.41B

HUM$239.53

Humana Inc.

+31.1%

YTD -9%$28.76B

UNH$363.87

UnitedHealth Group Incorporated

+29.3%

YTD +8%$330.28B

NVO$44.89

Novo Nordisk A/S

+22.4%

YTD -14%$151.36B

Bottom 1M Performers

Pressure

ABT$87.17

Abbott Laboratories

-14.8%

YTD -30%$151.59B

SYK$295.25

Stryker Corporation

-11.1%

YTD -15%$113.08B

BSX$55.98

Boston Scientific Corporation

-10.6%

YTD -41%$83.2B

MDT$77.79

Medtronic plc

-9.8%

YTD -19%$99.73B

DHR$174.63

Danaher Corporation

-9.1%

YTD -24%$123.6B

Live Screener

Rank the Biotech & Healthcare Stocks with live market and fundamental data

Scan the leaders, compare returns against growth and valuation, then open the full screener when you want to refine the universe.

46 stocks foundUpdated 2026-05-06T14:45:45.168Z

Open Full Screener →

Ticker	Company	Mkt Cap	YTD	Rev G TTM	Gross M	P/S
LLY	Eli Lilly and Company	$933.66B	-8.5%	47.4%	83.8%	14.3
ABBV	AbbVie Inc.	$364.63B	-10.1%	8.6%	70.2%	6.0
UNH	UnitedHealth Group Incorporated	$330.28B	8.2%	9.7%	18.5%	0.7
MRK	Merck & Co., Inc.	$279.49B	6.3%	1.2%	72%	4.3
AMGN	Amgen Inc.	$177.87B	0.6%	9.1%	70.8%	4.8
TMO	Thermo Fisher Scientific Inc.	$173.46B	-21.2%	5.4%	37.7%	3.9
GILD	Gilead Sciences, Inc.	$166.32B	9.8%	2.4%	78.3%	5.8
ISRG	Intuitive Surgical, Inc.	$160.32B	-19.7%	21.4%	66%	15.9
ABT	Abbott Laboratories	$151.59B	-29.8%	6.4%	50.8%	3.6
NVO	Novo Nordisk A/S	$151.36B	-14.3%	2.3%	81%	3.3
PFE	Pfizer Inc.	$150.4B	5%	1.4%	70.3%	2.4
DHR	Danaher Corporation	$123.6B	-24.2%	4%	60.9%	5.0
BMY	Bristol-Myers Squibb Company	$116.22B	6.5%	1.8%	67.6%	2.4
SYK	Stryker Corporation	$113.08B	-15.2%	11.2%	64%	4.5
VRTX	Vertex Pharmaceuticals Incorporated	$107.94B	-6.1%	10.4%	85%	8.9
CVS	CVS Health Corporation	$102.56B	0.7%	7.8%	13.8%	0.3
MDT	Medtronic plc	$99.73B	-19%	6.9%	65.3%	3.0
BSX	Boston Scientific Corporation	$83.2B	-40.9%	19.9%	69%	4.1
ELV	Elevance Health Inc.	$80.15B	4.2%	9.4%	25.6%	0.4
REGN	Regeneron Pharmaceuticals, Inc.	$72.97B	-9.5%	5.9%	85.4%	5.1
CI	Cigna Corporation	$72.68B	-1.2%	8.8%	9.5%	0.3
IDXX	IDEXX Laboratories, Inc.	$44.83B	-16%	13.1%	61.8%	10.4
ALNY	Alnylam Pharmaceuticals, Inc.	$40.18B	-24.8%	82.6%	81.8%	10.8
A	Agilent Technologies, Inc.	$33.27B	-14.8%	8.1%	52.4%	4.8
RVMD	Revolution Medicines, Inc.	$29B	86.3%	—	—	—
HUM	Humana Inc.	$28.76B	-9.4%	14.1%	14.5%	0.2
NTRA	Natera, Inc.	$28.44B	-9.6%	38.2%	60.3%	16.8
BIIB	Biogen Inc.	$27.92B	6.4%	0.4%	70.5%	2.8
VEEV	Veeva Systems Inc.	$27.83B	-22%	16.3%	75.5%	8.7
BNTX	BioNTech SE	$24B	-1.2%	4%	77.6%	7.5

See all 46 stocks →

Valuation Pulse

Are Biotech & Healthcare Stocks cheap or expensive right now?

Aggregated DCF intrinsic value and Wall Street analyst consensus across the theme universe — see where the opportunities and risks sit before you commit capital.

DCF Intrinsic Value

28 of 46 stocks with a DCF view

Median -7%

Undervalued

Fair Value

Overvalued

Wall Street Consensus

46 stocks with analyst coverage

Median +27%

Buy (41)Hold (5)

89%

Buy or Strong Buy

+27%

Median Target Upside

Biggest DCF Upside

Stocks the DCF model flags as most undervalued in this theme

Company	Price	DCF Value	Upside	Analyst	Mkt Cap
PFE Pfizer Inc.	$26.44	$49.14	+87%	Hold	$150.4B
INCY Incyte Corporation	$97.47	$146.99	+52%	Buy	$19.47B
MRK Merck & Co., Inc.	$113.16	$165.53	+48%	Buy	$279.49B
AMGN Amgen Inc.	$329.59	$475.94	+44%	Buy	$177.87B
BSX Boston Scientific Corporation	$55.98	$80.56	+43%	Buy	$83.2B

Daily Intelligence

What is driving the Biotech & Healthcare theme today

Start with the daily narrative, then review the setups across the value chain with catalyst and valuation context before you act.

Today's Brief

Apr 10, 2026

MIXED

Biotech healthcare stocks are driven by weight‑loss drug competition, dividend yields, and pipeline deals. Lilly and Novo Nordisk dominate the obesity market, with Lilly’s new pill expanding market share and Novo facing pricing pressure in India and the US markets. Amgen beats earnings estimates and gains China approval for a lung‑cancer drug, while AbbVie pulls ahead of Pfizer with a robust pipeline and attractive dividend. In contrast, Isrra is overvalued, with DCF valuing it far below market price, and BMY’s dividend appeal is muted by modest growth. Regulatory wins and earnings beats lift most names, but valuation concerns and pricing tests temper enthusiasm.

Top Drivers

LLY

Eli Lilly leads obesity drug race with new weight‑loss pill gaining market share.

NVO

Novo Nordisk faces pricing test as GLP‑1 drugs hit India and US markets.

AMGN

Amgen beats earnings estimates and secures China approval for lung‑cancer drug.

ABBV

AbbVie pulls ahead of Pfizer with strong pipeline and dividend appeal.

ISRG

Immunology leader Isrra is overvalued; DCF shows intrinsic value far below market price.

Featured Setups By Segment

Featured names with catalyst and valuation context

These are the cards worth scanning first: current narrative, Street target, VCP DCF view, peer-multiple verdict, and forward estimates in one place.

Large-Cap Pharma & Mega-Biotech

Established pharmaceutical companies and large-cap biotechs with diversified commercial portfolios, strong cash flows, and ongoing pipeline investment.

LLY

Eli Lilly and Company

$988.19$933.66B1M +7%

MIXED

Eli Lilly’s stock is being driven by its $2.3B acquisition of Ajax Therapeutics, expanding its oncology pipeline, and early launch data for new drugs, while traders anticipate significant price movement after earnings.

Street

Buy

Target $1258.47 • +27% • 45 analysts

VCP DCF

overvalued

-40% • FV $580.71

Peers

Overvalued

-22% • 81/100 confidence

VCP Est.

FY+1 Rev +14%

Base target $1641.35 • 63/100 confidence

Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings

investopedia.com • 2026-04-29 13:47

Overview DCF Relative Estimates

NVO

Novo Nordisk A/S

$44.89$151.36B1M +22%

MIXED

Novo Nordisk faces a near‑term shift: Health Canada’s approval of a generic Ozempic threatens current sales, but the company’s upcoming data on Wegovy and potential oral Ozempic/label expansions could revive growth. The market is weighing the generic risk against new product momentum.

Street

Buy

Target $47.00 • +5% • 39 analysts

VCP DCF

fair

+10% • FV $48.50

Peers

Undervalued

+679% • 85/100 confidence

VCP Est.

FY+1 Rev +8%

Base target $331.26 • 54/100 confidence

Meta is heading into earnings with a big move expected

gurufocus.com • 2026-04-29 14:11

Overview DCF Relative Estimates

ABBV

AbbVie Inc.

$206.15$364.63B1M -0%

BULLISH

AbbVie’s Q1 earnings beat estimates and the company raised its 2026 EPS outlook, driven by robust sales in immunology and neuroscience. A new FDA filing for Rinvoq in alopecia areata adds growth potential, while technical analysis signals a healthy trend‑following rebound.

Street

Buy

Target $256.64 • +24% • 41 analysts

VCP DCF

fair

-5% • FV $196.34

Peers

Overvalued

-33% • 80/100 confidence

VCP Est.

FY+1 Rev +8%

Base target $653.86 • 54/100 confidence

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

marketbeat.com • 2026-04-29 14:50

Overview DCF Relative Estimates

MRK

Merck & Co., Inc.

$113.16$279.49B1M -6%

NEUTRAL

No fresh company update today.

Street

Buy

Target $129.31 • +14% • 37 analysts

VCP DCF

undervalued

+48% • FV $165.53

Peers

Undervalued

+72% • 81/100 confidence

VCP Est.

FY+1 Rev +3%

Base target $133.43 • 56/100 confidence

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

zacks.com • 2026-04-29 07:21

Overview DCF Relative Estimates

Gene Therapy, mRNA, and Cell Editing

Next-generation platforms including mRNA therapeutics, CRISPR gene editing, base editing, RNA interference, and cell and gene therapy companies.

MRNA

Moderna, Inc.

$46.71$18.52B1M -4%

NEUTRAL

The headline concerns TG Therapeutics’ Q1 earnings expectations, which does not directly impact Moderna. No immediate catalyst for MRNA today.

Street

Hold

Target $36.00 • -23% • 27 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Undervalued

+35% • 58/100 confidence

VCP Est.

FY+1 Rev -18%

38/100 confidence

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

zacks.com • 2026-04-27 11:05

Overview DCF Relative Estimates

CRSP

CRISPR Therapeutics AG

$52.38$4.92B1M +7%

BULLISH

CRISPR Therapeutics (CRSP) rose on April 28 after reports it is expected to beat Q1 earnings estimates, with analysts citing a strong pipeline and positive guidance. The stock outperformed the broader market as investors reacted to the favorable earnings outlook.

Street

Buy

Target $63.00 • +20% • 38 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Undervalued

+757% • 45/100 confidence

VCP Est.

FY+1 Rev +17%

40/100 confidence

3 Growth Stocks That Could Generate 10X Returns

fool.com • 2026-04-29 11:00

Overview DCF Relative Estimates

ALNY

Alnylam Pharmaceuticals, Inc.

$301.11$40.18B1M -9%

BULLISH

ALNY is in focus as investors await Q1 earnings; analysts highlight that guidance and pipeline milestones could lift the stock if results beat estimates. Vertex's expected earnings growth may lift the biotech sector, adding supportive momentum for ALNY.

Street

Buy

Target $445.67 • +48% • 52 analysts

VCP DCF

fair

-3% • FV $286.01

Peers

Overvalued

-64% • 79/100 confidence

VCP Est.

FY+1 Rev +33%

Base target $301.11 • 52/100 confidence

Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

zacks.com • 2026-04-29 10:15

Overview DCF Relative Estimates

BNTX

BioNTech SE

$95.50$24B1M +5%

BULLISH

BNTX gains positive momentum as its ADC Trastuzumab Pamirtecan shows clinically meaningful efficacy in HER2+ recurrent endometrial cancer, boosting pipeline prospects.

Street

Buy

Target $137.13 • +44% • 24 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Overvalued

-44% • 66/100 confidence

VCP Est.

FY+1 Rev -11%

39/100 confidence

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

globenewswire.com • 2026-04-11 07:00

Overview DCF Relative Estimates

Small & Mid-Cap Biotech

Specialty biotechs with approved products or late-stage pipelines in oncology, rare diseases, CNS, and immunology.

BIIB

Biogen Inc.

$189.13$27.92B1M +10%

MIXED

Biogen beat Q1 earnings and revenue estimates, but trimmed its 2026 EPS outlook after factoring in acquisition-related charges, dampening upside.

Street

Buy

Target $211.42 • +12% • 48 analysts

VCP DCF

fair

-9% • FV $169.61

Peers

Undervalued

+14% • 80/100 confidence

VCP Est.

FY+1 Rev -1%

Base target $247.94 • 53/100 confidence

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

zacks.com • 2026-04-29 11:21

Overview DCF Relative Estimates

INCY

Incyte Corporation

$97.47$19.47B1M +3%

BULLISH

Incyte’s Q1 earnings and revenue beat estimates thanks to strong demand for its cancer drugs, boosting investor confidence ahead of upcoming conferences.

Street

Buy

Target $109.50 • +12% • 44 analysts

VCP DCF

undervalued

+52% • FV $146.99

Peers

Undervalued

+84% • 78/100 confidence

VCP Est.

FY+1 Rev +11%

Base target $135.92 • 61/100 confidence

Incyte to Present at Upcoming Investor Conferences

businesswire.com • 2026-04-29 08:00

Overview DCF Relative Estimates

NUVL

Nuvalent, Inc.

$101.47$6.74B1M -2%

BULLISH

Nuvalent’s submission of an NDA for Neladalkib in TKI‑pretreated advanced ALK‑positive NSCLC signals a key regulatory milestone, likely boosting the company’s pipeline prospects and valuation.

Street

Buy

Target $144.40 • +42% • 14 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Peer view unavailable

43/100 confidence

VCP Est.

Estimate view unavailable

Estimates unavailable

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

prnewswire.com • 2026-04-07 06:30

Overview DCF Relative Estimates

AXSM

Axsome Therapeutics, Inc.

$223.06$11.41B1M +31%

BEARISH

Analysts expect Axsome Therapeutics’ earnings to fall, citing weaker drug pipeline performance and slower clinical progress. Investors should watch for the upcoming earnings report and any updates on trial results or regulatory milestones.

Street

Buy

Target $225.86 • +1% • 25 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Overvalued

-47% • 58/100 confidence

VCP Est.

FY+1 Rev +37%

43/100 confidence

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

zacks.com • 2026-04-27 11:01

Overview DCF Relative Estimates

Medical Devices & Diagnostics

Surgical robotics, continuous glucose monitors, implants, imaging, and point-of-care diagnostics companies.

ISRG

Intuitive Surgical, Inc.

$451.38$160.32B1M -0%

NEUTRAL

No fresh company update today.

Street

Buy

Target $622.60 • +38% • 55 analysts

VCP DCF

overvalued

-54% • FV $210.28

Peers

Overvalued

-32% • 89/100 confidence

VCP Est.

FY+1 Rev +14%

Base target $677.29 • 80/100 confidence

Is ISRG's International Weakness a Temporary Drag or Structural Risk?

zacks.com • 2026-04-29 09:35

Overview DCF Relative Estimates

DXCM

DexCom, Inc.

$59.48$22.95B1M -6%

BULLISH

DexCom is being highlighted as a top value play, with analysts comparing it favorably to MASI and noting its long‑term upside potential.

Street

Buy

Target $80.88 • +36% • 52 analysts

VCP DCF

overvalued

-43% • FV $35.10

Peers

Undervalued

+107% • 81/100 confidence

VCP Est.

FY+1 Rev +13%

Base target $93.47 • 69/100 confidence

DXCM or MASI: Which Is the Better Value Stock Right Now?

zacks.com • 2026-04-29 12:41

Overview DCF Relative Estimates

ABT

Abbott Laboratories

$87.17$151.59B1M -15%

BULLISH

Abbott's FDA clearance and CE Mark for its next‑generation AI‑powered Ultreon 3.0 coronary imaging platform positions the company for growth in cardiac imaging, boosting investor confidence.

Street

Buy

Target $128.71 • +48% • 41 analysts

VCP DCF

fair

-2% • FV $87.61

Peers

Undervalued

+70% • 93/100 confidence

VCP Est.

FY+1 Rev +9%

Base target $85.27 • 54/100 confidence

How to Pick a Healthcare Stock That Can Weather Any Market

fool.com • 2026-04-28 09:45

Overview DCF Relative Estimates

SYK

Stryker Corporation

$295.25$113.08B1M -11%

NEUTRAL

Stryker (SYK) is in focus as investors anticipate Q1 earnings; analysts are scrutinizing revenue growth, operating margin, and product mix for guidance.

Street

Buy

Target $403.69 • +37% • 50 analysts

VCP DCF

fair

+13% • FV $332.26

Peers

Overvalued

-6% • 89/100 confidence

VCP Est.

FY+1 Rev +10%

Base target $470.37 • 78/100 confidence

Wall Street's Insights Into Key Metrics Ahead of Stryker (SYK) Q1 Earnings

zacks.com • 2026-04-27 10:15

Overview DCF Relative Estimates

Life Sciences Tools & Services

Instruments, consumables, lab automation, veterinary diagnostics, and cloud software for life sciences workflows.

TMO

Thermo Fisher Scientific Inc.

$466.76$173.46B1M -4%

BULLISH

Thermo Fisher’s launch of a U.S. flagship bioprocess design center and upcoming investor day signal new growth momentum, while the $1.08 B sale of its microbiology business trims costs and streamlines focus.

Street

Buy

Target $654.67 • +40% • 42 analysts

VCP DCF

overvalued

-18% • FV $385.18

Peers

Fair

+1% • 91/100 confidence

VCP Est.

FY+1 Rev +4%

Base target $589.37 • 68/100 confidence

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

businesswire.com • 2026-04-28 08:30

Overview DCF Relative Estimates

DHR

Danaher Corporation

$174.63$123.6B1M -9%

NEUTRAL

No material news for DHR today.

Street

Buy

Target $247.00 • +41% • 42 analysts

VCP DCF

overvalued

-34% • FV $115.14

Peers

Fair

-5% • 88/100 confidence

VCP Est.

FY+1 Rev +2%

Base target $245.76 • 62/100 confidence

Xylem Q1 Earnings Beat Estimates, Revenues Increase Y/Y

zacks.com • 2026-04-28 12:26

Overview DCF Relative Estimates

VEEV

Veeva Systems Inc.

$171.15$27.83B1M -2%

BEARISH

VEEV shares fell more than the market after an earnings miss and a downgrade in guidance, prompting a 6% drop in the stock.

Street

Buy

Target $280.10 • +64% • 42 analysts

VCP DCF

fair

-9% • FV $156.74

Peers

Undervalued

+29% • 81/100 confidence

VCP Est.

FY+1 Rev +14%

Base target $264.91 • 82/100 confidence

Veeva Systems (VEEV) Declines More Than Market: Some Information for Investors

zacks.com • 2026-04-28 18:47

Overview DCF Relative Estimates

AI-Driven Drug Discovery

Companies applying machine learning and AI to accelerate drug discovery, clinical trial design, and precision oncology diagnostics.

RXRX

Recursion Pharmaceuticals, Inc.

$3.37$1.78B1M +7%

NEUTRAL

RXRX stock is poised for a potential move as it prepares to report Q1 2026 results on May 6, with investors awaiting updates on business performance and financials.

Street

Hold

Target $11.00 • +226% • 10 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Undervalued

+73% • 54/100 confidence

VCP Est.

FY+1 Rev +32%

24/100 confidence

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

globenewswire.com • 2026-04-29 07:59

Overview DCF Relative Estimates

NTRA

Natera, Inc.

$206.77$28.44B1M +1%

BULLISH

Natera is positioned to tap a $20B MRD market, with analyst support and positive interim futility analysis from Allogene Therapeutics' MRD‑guided ALPHA3 trial in large B‑cell lymphoma, indicating strong demand for its MRD diagnostics.

Street

Buy

Target $262.50 • +27% • 27 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Overvalued

-78% • 61/100 confidence

VCP Est.

FY+1 Rev +32%

53/100 confidence

Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

benzinga.com • 2026-04-14 14:30

Overview DCF Relative Estimates

Guardant Health, Inc.

$89.52$11.19B1M -0%

BEARISH

Guardant Health shares fell on Tuesday after a scheduled investor conference and concerns about upcoming earnings, indicating potential underperformance.

Street

Buy

Target $133.14 • +49% • 30 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Overvalued

-25% • 58/100 confidence

VCP Est.

FY+1 Rev +35%

53/100 confidence

Guardant Health to Participate in Upcoming Investor Conferences

businesswire.com • 2026-04-29 16:05

Overview DCF Relative Estimates

Managed Care & Health Insurance

Managed care organizations and pharmacy benefit managers with large enrolled populations and cost-management scale.

UNH

UnitedHealth Group Incorporated

$363.87$330.28B1M +29%

BULLISH

UnitedHealth Group (UNH) is gaining momentum after strong Q1 earnings, driven by higher-than-expected Medicare Advantage enrollment and expansion of its Care Management services, prompting analysts to recommend buying.

Street

Buy

Target $385.43 • +6% • 52 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Fair

+4% • 86/100 confidence

VCP Est.

FY+1 Rev +3%

Base target $558.98 • 86/100 confidence

Opinion: It's Time to Load Up on UnitedHealth Group Stock

fool.com • 2026-04-29 15:35

Overview DCF Relative Estimates

Cigna Corporation

$275.66$72.68B1M -0%

MIXED

CI's stock is driven by Baron Capital’s 2025 Healthy Workforce designation, which may cut costs, while analysts focus on Q1 earnings and the potential impact of lower premiums on revenue.

Street

Buy

Target $328.00 • +19% • 39 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Undervalued

+62% • 85/100 confidence

VCP Est.

FY+1 Rev +7%

Base target $403.57 • 65/100 confidence

Baron Capital Recognized with 2025 Cigna Healthy Workforce Designation™

businesswire.com • 2026-04-29 09:00

Overview DCF Relative Estimates

ELV

Elevance Health Inc.

$369.07$80.15B1M +22%

BULLISH

ELV shares jumped 3.3% after the company reported a Q1 earnings beat, supported by a strong GF Score of 76 that signals solid fundamentals. Market optimism is reinforced by broader industry earnings momentum from peers like Centene and UHS.

Street

Buy

Target $382.38 • +4% • 37 analysts

VCP DCF

DCF unavailable

DCF view unavailable

Peers

Undervalued

+47% • 97/100 confidence

VCP Est.

FY+1 Rev +4%

Base target $486.45 • 80/100 confidence

Centene Q1 Earnings Beat Estimates on Rising Premiums, 2026 View Up

zacks.com • 2026-04-28 13:03

Overview DCF Relative Estimates

More Daily Summaries

Review the rest of the names in the theme that have fresh stock-level news coverage today.

AMGN

Amgen Inc.

MIXED

Amgen is in focus ahead of its Q1 earnings release, with analysts weighing the impact of a potential FDA withdrawal of its rare autoimmune drug and the prospects of a new cholesterol‑based heart drug that could drive future revenue.

Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?

zacks.com • 2026-04-28 13:15

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

zacks.com • 2026-04-28 07:20

CVS

CVS Health Corporation

MIXED

CVS faces a projected earnings decline, but the rollout of Magic Molecule’s FDA‑cleared hypochlorous acid skincare to 6,000 stores may offset pressure and boost revenue. Investor interest remains high, reflected in increased search volume.

Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for

zacks.com • 2026-04-29 11:02

Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know

zacks.com • 2026-04-29 10:01

HUM

Humana Inc.

BULLISH

Humana's Q1 earnings beat estimates due to higher premiums and a 1.5% revenue lift, while Medicare cost easing supports margin growth. EPS fell short of forecasts, slightly dampening enthusiasm.

Humana Beats Q1 Earnings Estimates on Increasing Premiums

zacks.com • 2026-04-29 13:36

Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

zacks.com • 2026-04-29 10:30

NTLA

Intellia Therapeutics, Inc.

MIXED

NTLA is trading lower after pricing its public offering and rolling BLA, despite strong Phase III HAE data, while market sentiment is mixed due to the new offering and regulatory updates.

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

globenewswire.com • 2026-04-29 07:00

NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA

zacks.com • 2026-04-28 14:06

PFE

Pfizer Inc.

MIXED

Positive late-stage trial results for blood cancer drug and improved PFS for ELREXFIO drive upside, but broader market sell‑off and short‑term volatility keep PFE down today.

Pfizer's blood cancer drug meets main goal in late-stage trial

reuters.com • 2026-04-29 07:42

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

businesswire.com • 2026-04-29 06:45

REGN

Regeneron Pharmaceuticals, Inc.

MIXED

Regeneron’s Q1 earnings beat expectations with strong sales of Dupixent and Eylea HD, but an FDA delay on the prefilled syringe and a setback for its flagship Eylea drug caused shares to slide today.

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

benzinga.com • 2026-04-29 13:57

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength

zacks.com • 2026-04-29 13:31

Earnings Calendar

Upcoming earnings across Biotech & Healthcare Stocks

Earnings are the single biggest catalyst for theme stocks. Track which names report soon and prepare before the move.

No earnings in the next 30 days

No names in this theme are scheduled to report in the next month.

Dates can shift, so if you are tracking a specific stock, open its page for the latest earnings calendar and setup.

Theme Breakdown

How the Biotech & Healthcare universe breaks down

These buckets separate the companies building, supplying, and monetizing the theme across the value chain.

Large-Cap Pharma & Mega-Biotech

Established pharmaceutical companies and large-cap biotechs with diversified commercial portfolios, strong cash flows, and ongoing pipeline investment.

LLYNVOABBVMRKAMGNGILDREGNVRTX

Gene Therapy, mRNA, and Cell Editing

Next-generation platforms including mRNA therapeutics, CRISPR gene editing, base editing, RNA interference, and cell and gene therapy companies.

MRNACRSPALNYBEAMNTLAEDITBNTX

Small & Mid-Cap Biotech

Specialty biotechs with approved products or late-stage pipelines in oncology, rare diseases, CNS, and immunology.

BIIBINCYNUVLBMRNAXSMRVMDEXEL

Medical Devices & Diagnostics

Surgical robotics, continuous glucose monitors, implants, imaging, and point-of-care diagnostics companies.

ISRGDXCMABTMDTSYKBSX

Life Sciences Tools & Services

Instruments, consumables, lab automation, veterinary diagnostics, and cloud software for life sciences workflows.

TMODHRAVEEVIDXX

AI-Driven Drug Discovery

Companies applying machine learning and AI to accelerate drug discovery, clinical trial design, and precision oncology diagnostics.

RXRXSDGRNTRAGH

Managed Care & Health Insurance

Managed care organizations and pharmacy benefit managers with large enrolled populations and cost-management scale.

UNHCVSCIHUMELV

How This Basket Is Built

Full healthcare ecosystem coverageThe basket spans large-cap pharma, gene therapy and editing, small/mid-cap biotechs with key catalysts, medical devices and diagnostics, life sciences tools and services, AI-driven drug discovery, and managed care. Stocks qualify when healthcare demand materially drives revenue and the investment thesis.
Pipeline and catalyst visibility emphasizedBiotech returns are dominated by binary pipeline events — Phase 3 readouts, FDA decisions, and NDA approvals. The table surfaces the metrics needed to track pipeline-stage companies alongside profitable large caps.
Listed common stocks onlyThe page focuses on listed equities with sufficient liquidity, analyst coverage, and financial disclosure to support real screening and valuation work.
Equal-weight theme basket for performanceThe performance chart equal-weights the basket so mega-cap names like LLY do not dominate the read, allowing investors to judge whether healthcare outperformance is driven by a single GLP-1 beneficiary or is broadly distributed.

Open Screener →

Quick Read

What Counts as a Biotech or Healthcare Stock

This page covers the full life sciences spectrum, from GLP-1 blockbusters to early gene editing platforms.

Large-cap pharma provides earnings stability and pipeline optionality
Gene therapy and mRNA represent the highest-growth, highest-risk segment
Devices, tools, and managed care offer more predictable compounding

Biotech and healthcare investing spans a wide risk spectrum. Large-cap pharma like LLY and NVO generates predictable cash flows from patent-protected blockbusters; clinical-stage gene editors trade almost entirely on pipeline optionality. Medical device leaders like ISRG and DXCM sit closer to SaaS in revenue predictability; tools companies like TMO and DHR are industrial-style compounders with sticky consumable revenue. All qualify when healthcare demand materially drives the investment thesis.

Quick Read

How to Evaluate Biotech and Healthcare Stocks

Revenue growth, R&D intensity, and pipeline stage are the key inputs — not just P/E ratios.

Revenue growth plus pipeline depth determines the long-run return profile
R&D as a percent of revenue shows investment intensity relative to peers
Binary catalyst risk (FDA decisions, Phase 3 readouts) dominates short-term moves

Pharma and large-cap biotech trade on earnings and pipeline optionality — a low P/E can still be expensive if a key patent expires in two years. Clinical-stage biotechs are valued on pipeline probability: Phase 3 timeline, estimated peak sales, and the market's implied success rate. Devices and tools companies trade more like SaaS — compare revenue growth, recurring revenue mix, and operating leverage. Use the screener to compare growth rates, margins, and EV/Sales side by side.

Quick Read

Key Risks in Biotech and Healthcare Stocks

Patent cliffs, trial failures, and pricing pressure are the three largest structural risks.

Patent cliffs erase revenue predictability for even the largest pharma names
Clinical trial failures cause 40-70% single-day declines for binary-risk biotechs
Drug pricing regulation can compress margins across the entire sector

Patent expirations are existential for large pharma: when a blockbuster loses exclusivity, revenue can fall 80% within 18 months. For clinical-stage biotechs, Phase 3 failure wipes most of the equity value in a single session. Managed care faces reimbursement regulation risk; tools companies are cyclically sensitive to biotech funding environments. Understanding which risk profile applies to each sub-sector is essential before sizing.

Frequently Asked Questions

Companies whose revenue is materially driven by pharmaceutical development and commercialization, medical device sales, life sciences tools and instrumentation, managed care enrollment, or AI-driven drug discovery. Spans a wide risk spectrum from defensive large-cap pharma (LLY, ABBV) to clinical-stage gene editing pure-plays (CRSP, NTLA).

Explore More Themes

39 stocks

AI Stocks: The US Theme Screener and Research Hub

Track US AI stocks with live market data, an equal-weight theme performance chart, daily theme intelligence, and a research-first stock table.

AiInnovation

20 stocks

Crypto Stocks: The Bitcoin and Blockchain Theme Screener and Research Hub

Research and screen crypto stocks in one place — Bitcoin miners, exchanges, blockchain companies, and digital-asset financials with live market data, theme performance, and daily intelligence in 2026.

CryptoInnovation

27 stocks

Cybersecurity Stocks: The Security Theme Screener and Research Hub

Research and screen cybersecurity stocks in one place — network security, endpoint detection, identity management, and cloud security companies with live market data, theme performance, and daily intelligence in 2026.

TechnologyGrowth

24 stocks

Data Center & AI Infrastructure Stocks: The AI Infrastructure Theme Screener and Research Hub

Research and screen data center and AI infrastructure stocks in one place — REITs, power management, cooling, networking, server hardware, and power utilities fueling the AI buildout with live market data, theme performance, and daily intelligence in 2026.

AiInfrastructure

32 stocks

Defense & Military Stocks: The Aerospace and Defense Screener and Research Hub

Research and screen defense stocks in one place — prime contractors, defense IT, military technology, and aerospace components with live market data, backlogs, dividends, and daily intelligence in 2026.

DefenseIndustrials

23 stocks

EV Stocks: The Electric Vehicle Theme Screener and Research Hub

Research and screen EV stocks in one place — live market data, equal-weight theme performance, daily intelligence, and a screener covering automakers, charging networks, battery suppliers, and electrification enablers in 2026.

InnovationGrowth

28 stocks

Fintech Stocks: The Fintech Theme Screener and Research Hub

Research and screen fintech stocks in one place — card networks, digital payments, neobanks, buy now pay later, payment processing, market infrastructure, and emerging market fintech with live market data, theme performance, and daily intelligence in 2026.

TechnologyGrowth

25 stocks

Gold & Precious Metals Stocks: The Gold & Precious Metals Theme Screener and Research Hub

Research and screen gold and precious metals stocks in one place — senior gold miners, silver producers, royalty and streaming companies, and critical minerals miners with live market data, theme performance, and daily intelligence in 2026.

Industrials

23 stocks

Nuclear Energy Stocks: The Nuclear Energy Theme Screener and Research Hub

Research and screen nuclear energy stocks in one place — nuclear power operators, uranium miners, small modular reactor developers, and nuclear services companies with live market data, theme performance, and daily intelligence in 2026.

EnergyInfrastructure

28 stocks

Oil & Gas Stocks: The Energy Sector Screener and Research Hub

Research and screen oil and gas stocks in one place — integrated majors, shale producers, pipeline operators, refiners, and oilfield services with live market data, dividends, and daily intelligence in 2026.

EnergyInfrastructure

14 stocks

Quantum Computing Stocks: The Quantum Computing Theme Screener and Research Hub

Research and screen quantum computing stocks in one place — pure-play quantum hardware companies, post-quantum cryptography, and diversified tech platforms investing in quantum with live market data, theme performance, and daily intelligence in 2026.

AiInnovation

28 stocks

Renewable Energy Stocks: The Clean Energy Theme Screener and Research Hub

Research and screen renewable energy stocks in one place — solar, wind, hydrogen, utilities, and storage companies with live market data, theme performance, and daily intelligence in 2026.

EnergyInfrastructure

25 stocks

Robotics & Automation Stocks: The Robotics & Automation Theme Screener and Research Hub

Research and screen robotics and automation stocks in one place — industrial automation, surgical robots, warehouse automation, semiconductor equipment, and AI-driven autonomous systems with live market data, theme performance, and daily intelligence in 2026.

AiInnovation

31 stocks

Space & Satellite Stocks: The Space Industry Screener and Research Hub

Research and screen space stocks in one place — launch providers, satellite operators, Earth observation companies, and aerospace crossovers with live market data, theme performance, and daily intelligence in 2026.

SpaceInnovation

Move From Theme Narrative to Stock Selection

Start with the basket, verify the drivers, then screen the names that still fit your process.

Open the Screener

Updated daily•Free access•No signup required